Citations

Clear

248 citation(s) found for "Bhatt, S".

Amplifying Our Voices: Fostering Advocacy in Infectious Diseases Fellowship
Paras, Molly L , Stead, Wendy , Bisono, Bismarck , Pottinger, Paul S. , Aziz, Rania S Abdel, Aziz, Mariam, Balba, Gayle , Blackburn, Brian G. , Butt, Saira , Chow, Brian , Graber, Christopher J. , Muñoz-Gómez, Sigridh , Pellegrino, Rachael , Schultz, Sara , Shnekendorf, Rachel, Jezek, Amanda, Martin, Allan , Group, For the Infectious Diseases Society of America Training Program Directors Community of Practice and Working, Angarone, Michael , Arnold, Forest, Bartash, Rachel , Bhanot, Nitin , Bhatt, Pinki J. , Bittner, Marvin J. , Blyth, Dana M , Carey, A., Cerne, Carlie, Donaghy, Henry, Echevarria, Leonor, Jose, Jo-Ann, Kodiyanplakkal, Rosy Priya , Román, F, Garcia, Luis Medina, Lora, Alfredo J Mena , Miko, Benjamin A. , Mitra, Subhashis , Osorio, Georgina, Patel, Mukesh, Pinargote, Paulette, Salas, Natalie Mariam , Sellers, Christopher J., Tang, Michael , Tischendorf, Jessica S , Trinh, Sonya, Viehman, J Alex, Vielemeyer, Ole, Wooten, Darcy , Bisono Garcia, Bismarck , Martin, Arlene , Luther, Vera P , Pottinger, Paul , Aziz, Rabita, Luther, Vera , Group, For the Infectious Diseases Society of America Training Program Directors Community of Practice and Working, Arnold, Forest, Bhowmick, Tanaya , Carey, Adrienne L, Dare, Ryan K , Jose, Jo-Ann, Gil, Raul Macias , Roman, Francisco Machiavello, Garcia, Luis Medina, Razonable, Raymund R. , Trinh, Sonya, Viehman, J Alex

Mayo Clinic

Open Forum Infectious Diseases | November 9, 2025 | Volume: 12 | Issue: 12 | Pages: No page available

10.1093/ofid/ofaf677 | PMID 41322240 Get It

Abstract Advocacy has long been at the core of the infectious diseases (ID) field, with clinicians and researchers advocating to ensure patients can access the care they need on an individual and global scale. The Infectious Diseases Society of America Training Program Directors’ (PD) Committee met in 2024 and discussed ways that advocacy is and should be incorporated into fellowship training, as well as highlighted the role PDs play in advocating for their trainees. Policies with a negative impact on ID clinical care, public health, and research underscore the importance of mobilizing the field of ID to advocate for the patients and communities we serve, as well as for ourselves. This paper presents ideas generated at this meeting and is meant to serve as a reference for ID PDs, as well as the wider ID community, as a call to action for teaching and participating in advocacy work.
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy
Davis, Margot K. , Akinboboye, Olakunle O., Bhatt, Kunal , Fontana, Marianna, Gillmore, Julian D., Griffin, Jan M. , Grodin, Justin L. , Lam, Kaitlyn, Masri, Ahmad , Ruberg, Frederick L. , Sarswat, N., Shah, Keyur B. , Soman, Prem, Xiong, Kuangnan, Cao, Xiaofan, Lystig, Ted, Tamby, Jean‐François, Castaño, Adam , Katz, Leonid , Sinha, Uma, Fox, Jonathan C., Solomon, Scott D. , Grogan, Martha, Gillmore, Julian D , Alexander, Kevin M , Berk, John L. , Cappelli, Francesco, Cuddy, Sarah A. M. , Fontana, Marianna , Garcia-Pavia, Pablo , Gillmore, Julian D. , Judge, Daniel P. , Khouri, Michel G. , Maurer, Matthew J. , Obici, Laura , Soman, Prem , Stern, Lily Kagan , Wright, Richard, Lystig, Ted, Solomon, Scott David , Grogan, Martha

Mayo Clinic

JAMA Cardiology | November 8, 2025 | Volume: 11 | Issue: 1 | Pages: 57

10.1001/jamacardio.2025.4477 | PMID 41205147 Get It

Importance Transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease caused by misfolded transthyretin (TTR), occurs as wild-type (ATTRwt-CM) or variant (ATTRv-CM) forms. p.Val142Ile is the most common variant in the US, linked to rapid progression and increased mortality. Acoramidis achieves near-complete (≥90%) TTR stabilization and showed clinical benefit in the 30-month ATTRibute-CM trial and through month 42 in the ongoing open-label extension (OLE). Objective To evaluate the efficacy of acoramidis in ATTRwt-CM, ATTRv-CM, and variant subgroups (p.Val142Ile and non-p.Val142Ile). Design, Setting, and Participants This international, multicenter, phase 3, randomized placebo-controlled study took place from April 2019 to May 2023 with ongoing OLE (month 42). ATTRibute-CM enrolled 632 participants with ATTR-CM; 611 of 632 were included in the modified intention-to-treat (mITT) population. There were 380 participants who continued into the OLE. These data were analyzed from January 2025 to July 2025. Interventions Oral acoramidis, 712 mg, or placebo twice daily for 30 months, followed by 12 months of open-label treatment. Main Outcomes and Measures All-cause mortality (ACM), cardiovascular-related hospitalizations (CVH), serum TTR, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire Overall Summary score, and N-terminal pro B-type natriuretic peptide in participants with ATTRwt-CM and ATTRv-CM. Post-hoc analyses were conducted in variant subgroups, including p.Val142Ile. Results Overall, 552 participants with wild-type ATTR-CM (mean [SD] age, 78 [6.3] years; 92.0% male and 8.0% female) and 59 participants with variant ATTR-CM (mean [SD] age, 73 [7.7] years; 77.3% male and 22.7% female) were randomized (mITT population), including 35 with p.Val142Ile. Consistent efficacy was observed in wild-type and variant subgroups for ACM/CVH through month 30 and ACM through month 42. At month 30, acoramidis reduced the risk of ACM/first CVH vs placebo by 31% in ATTRwt-CM (hazard ratio [HR], 0.69; 95% CI, 0.52-0.90; P = .007) and by 59% in ATTRv-CM (HR, 0.41; 95% CI, 0.21-0.81; P = .01). ACM was reduced through month 42 with HRs of 0.70 (95% CI, 0.50-0.98; P = .04) and 0.41 (95% CI, 0.19-0.93; P = .03) in the ATTRwt-CM and ATTRv-CM groups, respectively. Consistent treatment benefit was observed in participants with ATTRwt-CM and ATTRv-CM for secondary end points. Within variant subgroups (p.Val142Ile vs non-p.Val142Ile), consistent treatment benefits were observed for ACM/CVH through month 30 and ACM through month 42. Conclusions and Relevance The beneficial effect of acoramidis was observed consistently in ATTRwt-CM and ATTRv-CM groups. These hypothesis-generating results indicate that further studies are warranted to better characterize the therapeutic benefit of acoramidis in variant subgroups. Trial Registration ClinicalTrials.gov Identifiers: NCT03860935 ; NCT04988386
Abstract 4365531: Acoramidis Effect on All-Cause Mortality in Patients with p.V142I (V122I) Variant ATTR-CM: Findings From the ATTRibute-CM Study
Alexander, Kevin, Sarswat, Nitasha, Davis, Margot, Cuddy, Sarah, Kittleson, Michelle, Shah, Keyur, Griffin, Jan, Ruberg, Frederick, Khouri, Michel, Bhatt, Kunal, Judge, Daniel, Grodin, Justin, Akinboboye, Olakunle, Chen, Chris, Tamby, Jean-Francois, Castano, Adam, Fox, Jonathan, Fontana, Marianna, Gillmore, Julian, Grogan, Martha, Solomon, Scott, Gillmore, Julian D , Alexander, Kevin, Sarswat, Nitasha, Davis, Margot, Cuddy, Sarah, Kittleson, Michelle, Shah, Keyur, Griffin, Jan, Ruberg, Frederick, Khouri, Michel, Bhatt, Kunal, Judge, Daniel P. , Grodin, Justin, Akinboboye, Olakunle, Chen, Chris, Tamby, Jean-Francois, Castano, Adam, Fox, Jonathan, Fontana, Marianna, Gillmore, Julian D. , Grogan, Martha, Solomon, Scott

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4365531 Get It

Introduction: Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) arises from amyloidogenic aggregates of destabilized TTR protein in variant (ATTRv-CM) or acquired wild-type TTR (ATTRwt-CM). The p.V142I (V122I) variant is the most common pathogenic TTR allele in the USA and has higher mortality vs wild type. Acoramidis, an oral TTR stabilizer achieving ≥90% stabilization, is approved in USA, UK, Europe, and Japan for treating ATTR-CM in adults. In ATTRibute-CM (NCT03860935), acoramidis showed a reduction in all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH) vs placebo (PBO), with consistent benefit in ATTRwt-CM and ATTRv-CM (all variants). We report clinical outcomes in participants with p.V142I ATTRv-CM. Research Question: What was the efficacy of acoramidis for clinical outcomes (ACM, CVH) in participants with p.V142I ATTRv-CM in ATTRibute-CM? Methods: In ATTRibute-CM, 632 participants were randomized 2:1 to receive acoramidis HCl 800 mg or PBO twice daily for 30 months. All participants enrolled in open-label extension (OLE) received acoramidis only. Exploratory post hoc analyses were done in the p.V142I ATTRv-CM subgroup. Time-to-event analyses used a stratified Cox proportional hazards model using treatment group as an explanatory factor and baseline 6MWD as a covariate, stratified by randomization factors: serum NT-proBNP and eGFR. ACM was analyzed at Month 42 (ATTRibute-CM 30 months + 12 months OLE). Results: Of the 59 patients with ATTRv-CM reported at randomization, 35 (59.3%) had p.V142I (23 acoramidis, 12 PBO) with comparable baseline characteristics; 4 were homozygous for p.V142I (1 acoramidis, 3 PBO). Through Month 30, ACM/first CVH occurred in 43.5% (10/23) of acoramidis vs 83.3% (10/12) in PBO (HR 0.311; 95% CI 0.120–0.805; Figure 1 ). Through Month 42, ACM occurred in 26.1% (6/23) of continuous acoramidis vs 66.7% (8/12) in PBO to acoramidis (HR 0.307; 95% CI 0.097–0.973; Figure 2 ). Conclusions: In participants with p.V142I ATTRv-CM, acoramidis use was associated with 69% risk reduction in ACM/first CVH through Month 30 and ACM through Month 42 vs PBO. This is the first report of clinical benefit of this magnitude observed in this high-risk population. These findings have biologic plausibility and may reflect the near-complete stabilization observed experimentally with acoramidis in p.V142I ATTR fibrils. These observations require confirmation in larger cohort studies.
Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation
Strouse, Christopher , Logan, Brent R. , Estrada‐Merly, Noel, Peterson, Andrew C. , Preussler, Jaime M. , Truong, Tony H. , Khera, Nandita , Wood, William A. , Rangarajan, Hemalatha G. , Akard, Luke P., Sharma, Akshay , Rizzo, J. Douglas , Saber, Wael , Logan, Brent , Estrada-Merly, Noel , Preussler, Jaime M , Truong, Tony H , Khera, Nandita , Wood, William A , Bhatt, Neel S , Sharma, Akshay , Rizzo, J Douglas , Saber, Wael , Strouse, Christopher S , Juckett, Mark , Peterson, Andrew, Troy, Jesse D , Bhatt, Neel S.

Mayo Clinic

JCO Oncology Practice | October 2, 2025 | Volume: 22 | Issue: 5 | Pages: 844-851

10.1200/op-25-00115 | PMID 41037768 Get It

PURPOSE Public reporting of health care outcomes can have unintended effects such as inappropriate risk aversion in patient selection. METHODS The center-specific survival analysis annually assigns all hematopoietic cell transplantation (HCT) centers in the United States a +1, −1, or 0 score for observed outcomes that are above, below, or within a center-specific predicted range of outcome. For each index year (2012-2016), centers receiving a −1 score after 0 scores in the preceding 2 years were compared with contemporaneous centers with as-predicted outcomes (0 score). Changes in the patient population characteristics in the 3 years before versus the 3 years after the index years were compared between the newly below-expected centers (NBCs) and the controls. A multivariate model adjusted for baseline patient population characteristics and center volume. RESULTS No differences in patient selection behavior were identified when comparing the NBCs with the controls across eight key patient population characteristics. For the statistically modeled (predicted) 1-year overall survival (OS), reflecting a holistic measure of centers' patient population risk, we observed no statistically significant difference in change (−0.23% [95% CI, −1.4 to 0.9]; P = .70). The observed OS increased in both NBCs and controls by 0.9% and 4.5%, respectively, without statistically significant difference in change. CONCLUSION Centers receiving a −1 score were not observed to deviate significantly from patient selection trends in the HCT field. These findings suggest that public reporting of HCT outcomes in the United States does not result in unintended bias against HCT for high-risk patients.
Defining IgM Multiple Myeloma
Bhatt, Mahin , Zimmowitch, Anaelle, Audil, Hadiyah Y. , Rajkumar, S. Vincent , Audil, Hadiyah Yasin , Rajkumar, S Vincent , Zimmowitch, Anaëlle

Mayo Clinic

American Journal of Hematology | October 1, 2025 | Volume: 100 | Issue: 12 | Pages: 2375-2376

10.1002/ajh.70097 | PMID 41031742 Get It

Antiphospholipid antibody-related clinical manifestations during childhood versus adulthood: descriptive results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository
Bhatt, Jheel Pandya, Dale, Marissa, Clarke, Ann E. , Aguirre-Zamorano, María Ángeles, Kello, Nina , Wahl, Denis, Branch, Ware, Zhang, Zhuoli , Atsumi, Tatsuya , Pazzola, Giulia, Nalli, Cecilia , Rodríguez-Almaraz, Esther , Petri, Michelle, Artım-Esen, Bahar , Zuo, Yu , Willis, Rohan , Barber, Megan R.W. , Anunciación-Llunell, Ariadna , Erkan, Doruk , Zuo, Yu , Bhatt, Jheel Pandya, Andrade, Danieli , Tektonidou, Maria G. , Pengo, Vittorio , Sciascia, Savino , Gea, Josep Pardos , Paredes, D. , Belmont, H. Michael , Fortin, Paul R. , Wahl, Denis , Gerosa, Maria , Jesús, Guilherme Ramires de , Efthymiou, Maria , Duarte‐García, Alí , Petri, Michelle , Cervera, Ricard , Pons‐Estel, Guillermo , Shi, Hui , Skeith, Leslie , Radin, Massimo , Bertolaccini, Maria Laura , Cohen, Hannah

Mayo Clinic

Clinical and Experimental Rheumatology | July 30, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/t46qkf | PMID 40737058 Get It

Mission Impossible: Endoscopic Restoration of Gastrointestinal Lumen Continuity
Chopra, Preeyati , Buttar, Davekaran, Bhatt, Mahin C., Ohri, Ashwariya , Buttar, Navtej , Goyal, Mayank, Bhatt, Mahin C., Dayyeh, Barham K. Abu , Vargas, Eric J.

Mayo Clinic

ACG Case Reports Journal | July 9, 2025 | Volume: 12 | Issue: 7 | Pages: e01763

10.14309/crj.0000000000001763 Get It

ABSTRACT Anastomotic leaks following complex gastrointestinal surgeries pose a significant challenge, especially in patients unfit for further surgical intervention. We present a novel 3-staged endoscopic approach to restore gut continuity in a 55-year-old woman with multiple anastomotic leaks and discontinuous bowel segments following extensive abdominal surgeries. The procedure included stent placement, endoscopic ultrasound (EUS)-guided gastrojejunostomy with a lumen-apposing metal stent (LAMS), and fistula plug insertion with glue. Over 6 months, bowel continuity was restored, and at 6-year follow-up, the patient remains symptom free, tolerating oral intake. This case demonstrates the transformative potential of advanced endoscopic techniques in managing complex gastrointestinal disruptions without further surgery.
Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice
Borogovac, Azra , Efebera, Yvonne A. , DeSalvo, Anna M. , Foley, Amy , Stewart, Valerie , Hamilton, Betty K. , Heuer, Mykala, Molfenter, Todd , Ragon, Brittany Knick , Wall, Sarah , Khera, Nandita , Horowitz, Mary M. , DeZern, Amy E., Bhatt, Neel S , DeSalvo, Anna , Hamilton, Betty K , Molfenter, Todd , Wall, Sarah A , Broglie, Larisa A , Juckett, Mark , Bhatt, Neel S. , Devine, Steven M. , Heuer, Mykala, Plastaras, John Peter , Broglie, Larisa , Dezern, Amy Elizabeth

Mayo Clinic

Blood Advances | June 24, 2025 | Volume: 9 | Issue: 17 | Pages: 4448-4457

10.1182/bloodadvances.2024015405 | PMID 40554428 Get It

Abstract Severe aplastic anemia (SAA) is a rare and life-threatening bone marrow failure disorder. Immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporine has long been a frontline treatment option in SAA; however, its limited durability and risk of long-term complications such as secondary malignancies remain a drawback in this treatment modality. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative option with significantly improved outcomes over the long term, particularly with HLA-matched related donors. However, the use of alternative donors, such as haploidentical, mismatched, or matched unrelated donors, has previously been limited due to increased transplant-related morbidity, particularly graft-versus-host disease (GVHD). HCTs have therefore been limited to young recipients and those with HLA-matched related donors, creating significant disparity for older adults and those who lack matched donor options. Nevertheless, more recent advances in HCT, such as posttransplant cyclophosphamide for GVHD prophylaxis, have led to improved outcomes of HCT with alternative donors; however, alternative donor HCT remains underused as up-front therapy, in part because of limited multicenter trial data. This review discusses current SAA treatment approaches, including both IST and HCT, and highlights remaining gaps. It also discusses how ongoing clinical trials such as CureAA and TransIT could help address these gaps. Furthermore, we discuss the importance of stakeholder engagement and implementation science in the integration of research-based evidence into clinical practice. Bridging these gaps is necessary for achieving equitable access for patients historically excluded from frontline HCT, including older adults and racially or ethnically diverse populations.
Surgical Management of a Painful Temporal Bone En Plaque Meningioma: A Case Report and Review of the Literature
Wilson, Penny , Edgar, Mark A. , Quiñones-Hinojosa, Alfredo , Raymond, Mallory , Wilson, Prishae , Quiñones-Hinojosa, Alfredo , Bhatt, Alok A. , Almeida, João Paulo , Raymond, Mallory J

Mayo Clinic

Journal of Neurological Surgery Reports | June 16, 2025 | Volume: 86 | Issue: 02 | Pages: e122-e126

10.1055/a-2625-9498 | PMID 40524895 Get It

AbstractTemporal bone en plaque meningiomas can present management challenges, particularly when accompanied by severe pain. We report the case of a 42-year-old woman who was initially diagnosed with chronic otitis media but was later found to have a painful left temporal bone en plaque meningioma. Despite conservative therapy, her pain progressed, prompting the decision to undergo surgical resection, which resulted in considerable pain relief. This report illustrates the influence of pain on surgical decision-making for temporal bone en plaque meningiomas and reviews the literature on their variable presentations and management strategies.
Fulminant Cerebral Edema From Hyperammonemia in Alpha-1-antitrypsin Deficiency Related Cirrhosis and Adynamic Ileus After Gastrointestinal Bleeding
Al-Asaad, Abdullah , Rigby, Mark , Bhatt, S., Bauer, Philippe R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3885-A3885

10.1164/ajrccm.2025.211.abstracts.a3885 Get It

Abstract Background Intracranial hypertension from cerebral edema is a feared complication in patients with acute liver failure. Diagnosing cerebral edema in critically ill patients can be challenging as it may be insidious in onset. We present a case of fulminant hyperammonemia-induced cerebral edema in a patient with newly diagnosed alpha-1-antitrypsin deficiency (A1AD) in the setting of intestinal ileus and ineffective lactulose therapy. Case A 48-year-old male with newly diagnosed A1AD-related cirrhosis, alcohol use, and obesity (BMI 48.9) presented at an outside facility with altered mental status. Physical exam showed waxing and waning mentation, and serum ammonia was 245 mcmol/L. Upon transfer to our facility, hemoglobin was 10.3 g/dL, creatinine 1.77 mg/dL, total bilirubin 1.5 mg/dL, INR 1.2, ALT 60 U/L, AST 107 U/L, ALP 173 U/L, and serum ammonia 138 mcmol/L. Serum alpha-1-antitrypsin returned at 41 mg/dL with SZ phenotype. Abdominal ultrasound showed cirrhosis with moderate ascites. Paracentesis demonstrated no acute peritonitis. After initiation of lactulose and rifaximin, his mental status improved initially. However, he experienced 2 episodes of coffee-ground emesis with hemoglobin dropping to 7.0 g/dL requiring blood transfusions. Urgent esophagogastroduodenoscopy, limited by large residual contents, found no active bleed. A nasogastric tube was placed. CT abdomen pelvis showed diffuse colonic and small bowel dilation consistent with adynamic ileus impairing lactulose administration. His mental status worsened, necessitating ICU transfer and intubation for airway protection. Serum ammonia peaked at 397 mcmol/L. Neostigmine did not restore any effective bowel movement, and continuous renal replacement therapy was initiated to control the hyperammonemia. A convulsive episode prompted imaging. Head CT showed diffuse cerebral edema, later confirmed on MRI (Figure 1). Continuous electroencephalogram showed diffuse slowing without epileptiform discharges. His protracted hospital course was marked by minimal neurological recovery requiring tracheostomy and ongoing supportive measures per family wishes. Discussion Cerebral edema is one of the leading causes of morbidity and mortality in patients with severe hyperammonemia, which can result in irreversible cortical and deep grey matter injury that typically spares perirolandic and medial occipital regions. Although the exact mechanism continues to be researched elevated serum ammonia plays a critical role in disrupting the innate cerebral autoregulation. Prompt diagnosis and early intracranial pressure control (head of the bed elevation, hyperventilation, mannitol, hypertonic saline) are paramount. Typical hyperammonemia treatment includes lactulose, rifaximin, or polyethylene glycol, and correction of any precipitating factors. Dialysis should be considered early to prevent cerebral toxicity in hyperammonemia refractory to conventional treatments.